Prognostic Analysis and Biomarkers Identification of Immune Infiltration in Early and Late Stage Hepatocellular Carcinoma Based on TCGA Data

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Guo T, Zhang Z, Zhu L, et al. TRIM55 suppresses malignant biological behavior of lung adenocarcinoma cells by increasing protein degradation of Snail1. Cancer Biol Ther. 2022;2022:1–10.
   Google Scholar
• Li N, Wang J, Zhan X. Identification of immune-related gene signatures in lung adenocarcinoma and lung squamous cell carcinoma. Front Immunol. 2021;12:752643. doi:10.3389/fimmu.2021.752643
   PubMed Web of Science ®Google Scholar
• Li X, Huang L, Gao W. Overexpression of tripartite motif containing 55 (TRIM55) inhibits migration and invasion of hepatocellular carcinoma (HCC) cells via epithelial-mesenchymal transition and matrix metalloproteinase-2 (MMP2). Med Sci Monit. 2019;25:771–777. doi:10.12659/MSM.910984
   PubMed Web of Science ®Google Scholar
• Ding GY, Zhu XD, Ji Y, et al. Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Ann Tran Med. 2020;8:204. doi:10.21037/atm.2020.01.44
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ying X, Zhao Q, et al. Identification of protein expression changes in hepatocellular carcinoma through iTRAQ. Dis Markers. 2020;2020:2632716. doi:10.1155/2020/2632716
   PubMed Web of Science ®Google Scholar
• Yu D, Green B, Marrone A, et al. Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep. 2015;5:8534. doi:10.1038/srep08534
   PubMed Web of Science ®Google Scholar
• Wang X, Yu T, Liao X, et al. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma. Cancer Med. 2018;7:966–980. doi:10.1002/cam4.1299
   PubMed Web of Science ®Google Scholar
• Ceylan H. Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis. Med Oncol. 2021;38:63. doi:10.1007/s12032-021-01510-0
   PubMed Web of Science ®Google Scholar
• Shen H, Wu H, Sun F, et al. A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma. Bioengineered. 2021;12:240–251. doi:10.1080/21655979.2020.1866303
   PubMed Web of Science ®Google Scholar
• Mu D, Qin F, Li B, et al. Identification of the sixth complement component as potential key genes in hepatocellular carcinoma via bioinformatics analysis. Biomed Res Int. 2020;2020:7042124. doi:10.1155/2020/7042124
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu JL, Wang J. SAPCD2 promotes invasiveness and migration ability of breast cancer cells via YAP/TAZ. Eur Rev Med Pharmacol Sci. 2020;24:3786–3794. doi:10.26355/eurrev_202004_20844
   PubMedGoogle Scholar
• Zhu B, Wu Y, Niu L, et al. Silencing SAPCD2 represses proliferation and lung metastasis of fibrosarcoma by activating hippo signaling pathway. Front Oncol. 2020;10:574383. doi:10.3389/fonc.2020.574383
   PubMed Web of Science ®Google Scholar
• Luo Y, Wang L, Ran W, et al. Overexpression of SAPCD2 correlates with proliferation and invasion of colorectal carcinoma cells. Cancer Cell Int. 2020;20:43. doi:10.1186/s12935-020-1121-6
   PubMed Web of Science ®Google Scholar
• Sun Z, Mao Y, Zhang X, et al. Identification of ARHGEF38, NETO2, GOLM1, and SAPCD2 associated with prostate cancer progression by bioinformatic analysis and experimental validation. Front Cell Develop Bio. 2021;9:718638. doi:10.3389/fcell.2021.718638
   PubMed Web of Science ®Google Scholar
• Li L, Cao Y, Fan Y, et al. Gene signature to predict prognostic survival of hepatocellular carcinoma. Open Med. 2022;17:135–150. doi:10.1515/med-2021-0405
   Web of Science ®Google Scholar
• Wang Y, Yang H, Zhang G, et al. hsa-miR-7-5p suppresses proliferation, migration and promotes apoptosis in hepatocellular carcinoma cell lines by inhibiting SPC24 expression. Biochem Biophys Res Commun. 2021;561:80–87. doi:10.1016/j.bbrc.2021.05.020
   PubMed Web of Science ®Google Scholar
• Zhang X, Ma L, Zhai L, et al. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. Int J Med Sci. 2021;18:984–999. doi:10.7150/ijms.49126
   PubMed Web of Science ®Google Scholar
• Jiang W, Wen D, Gong L, et al. Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET. Biochem Biophys Res Commun. 2018;500:211–216. doi:10.1016/j.bbrc.2018.04.041
   PubMed Web of Science ®Google Scholar
• Yin J, Liu Q, Chen C, et al. Small regulatory polypeptide of amino acid response negatively relates to poor prognosis and controls hepatocellular carcinoma progression via regulating microRNA-5581-3p/human cardiolipin synthase 1. J Cell Physiol. 2019;234:17589–17599. doi:10.1002/jcp.28383
   PubMed Web of Science ®Google Scholar
• Dong Z, Yang J, Zheng F, et al. The expression of lncRNA XIST in hepatocellular carcinoma cells and its effect on biological function. J BUON. 2020;25:2430–2437.
   PubMed Web of Science ®Google Scholar
• Wang J, Yin G, Bian H, et al. LncRNA XIST upregulates TRIM25 via negatively regulating miR-192 in hepatitis B virus-related hepatocellular carcinoma. Molecul Med. 2021;27:41. doi:10.1186/s10020-021-00278-3
   PubMed Web of Science ®Google Scholar
• Liu WG, Xu Q. Long non-coding RNA XIST promotes hepatocellular carcinoma progression by sponging miR-200b-3p. Eur Rev Med Pharmacol Sci. 2019;23:9857–9862. doi:10.26355/eurrev_201911_19549
   PubMedGoogle Scholar
• Ding S, Jin Y, Hao Q, et al. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis. Cancer Cell Int. 2020;20:6. doi:10.1186/s12935-019-1081-x
   PubMed Web of Science ®Google Scholar
• Dai W, Dai JL, Tang MH, et al. lncRNA-SNHG15 accelerates the development of hepatocellular carcinoma by targeting miR-490-3p/ histone deacetylase 2 axis. World J Gastroenterol. 2019;25:5789–5799. doi:10.3748/wjg.v25.i38.5789
   PubMed Web of Science ®Google Scholar